Trial Profile
Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human polyomavirus infections
- Focus Pharmacodynamics; Registrational
- 08 Aug 2019 Long-term follow-up results (n=37) published in the Vaccine.
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 25 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.